INmune Bio, Inc. (NASDAQ:INMB) Short Interest Update

Key Points

• INmune Bio's short interest dropped by 29.8% in August, totaling 3,740,000 shares, with 21.9% of the company's stock currently short sold.
• The company's stock has a consensus rating of "Moderate Buy" with an average price target of $18.40, although recent ratings have included downgrades to "sell" from several analysts.
• After reporting an EPS of ($0.34) for the last quarter, INmune Bio is projected to post -2.24 EPS for the current year.

INmune Bio, Inc. (NASDAQ:INMB - Get Free Report) saw a significant decrease in short interest in August. As of August 31st, there was short interest totaling 3,740,000 shares, a decrease of 29.8% from the August 15th total of 5,330,000 shares. Based on an average daily trading volume, of 3,410,000 shares, the short-interest ratio is currently 1.1 days. Approximately 21.9% of the company's shares are sold short. Approximately 21.9% of the company's shares are sold short. Based on an average daily trading volume, of 3,410,000 shares, the short-interest ratio is currently 1.1 days.

Wall Street Analysts Forecast Growth

INMB has been the subject of a number of research reports. Raymond James Financial downgraded shares of INmune Bio from a "moderate buy" rating to a "hold" rating in a research note on Monday, June 30th. Scotiabank reiterated a "sector underperform" rating on shares of INmune Bio in a report on Tuesday, July 1st. Maxim Group dropped their target price on shares of INmune Bio from $30.00 to $8.00 and set a "buy" rating on the stock in a report on Wednesday, July 2nd. BTIG Research reiterated a "neutral" rating on shares of INmune Bio in a research report on Tuesday, July 1st. Finally, Wall Street Zen downgraded shares of INmune Bio from a "hold" rating to a "sell" rating in a research report on Saturday, August 2nd. One investment analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $18.40.

INmune Bio Stock Down 3.6%

NASDAQ INMB traded down $0.07 on Friday, reaching $1.90. The company had a trading volume of 1,051,609 shares, compared to its average volume of 810,449. The stock has a market capitalization of $50.50 million, a PE ratio of -0.77 and a beta of 1.03. The firm's 50 day moving average price is $2.32 and its 200 day moving average price is $5.38. INmune Bio has a 12 month low of $1.71 and a 12 month high of $11.64.

INmune Bio (NASDAQ:INMB - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.37) by $0.03. On average, research analysts expect that INmune Bio will post -2.24 EPS for the current year.

Hedge Funds Weigh In On INmune Bio

A number of institutional investors and hedge funds have recently made changes to their positions in INMB. XTX Topco Ltd grew its stake in shares of INmune Bio by 240.9% in the 2nd quarter. XTX Topco Ltd now owns 125,847 shares of the company's stock worth $291,000 after buying an additional 88,928 shares in the last quarter. Millennium Management LLC boosted its stake in shares of INmune Bio by 43.9% during the 4th quarter. Millennium Management LLC now owns 291,327 shares of the company's stock worth $1,360,000 after purchasing an additional 88,823 shares during the period. JPMorgan Chase & Co. boosted its stake in shares of INmune Bio by 1,042.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 73,097 shares of the company's stock worth $169,000 after purchasing an additional 66,700 shares during the period. Two Sigma Investments LP boosted its stake in shares of INmune Bio by 444.8% during the 4th quarter. Two Sigma Investments LP now owns 66,384 shares of the company's stock worth $310,000 after purchasing an additional 54,200 shares during the period. Finally, PNC Financial Services Group Inc. purchased a new position in shares of INmune Bio during the 2nd quarter worth about $87,000. 12.72% of the stock is owned by hedge funds and other institutional investors.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.